What adjuvants and preservatives were used in 2020–2021 COVID-19 vaccines and why?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Between 2020 and 2021, the dominant COVID-19 vaccines used three broad formulation approaches: mRNA (Pfizer‑BioNTech, Moderna), adenoviral vectors (Johnson & Johnson, AstraZeneca, Sputnik V), and protein‑subunit or inactivated candidates (Novavax, others). The mRNA vaccines contained no traditional adjuvants or preservatives but did include lipid nanoparticles and PEG‑containing lipids to deliver RNA [1] [2]. Protein‑based vaccines relied on established adjuvants such as Matrix‑M (saponin‑based) or MF59/AS03 variants to boost weaker protein antigens [1] [3] [4].
1. Why adjuvants mattered: turning weak proteins into protective vaccines
Protein subunit and many inactivated vaccines are intrinsically less immunogenic than whole‑virus vaccines; adjuvants were therefore essential to strengthen and shape immune responses and reduce required antigen doses. Reviews and clinical trials from 2020–2021 explain that adjuvants like Matrix‑M, MF59, AS03 and CpG‑type TLR agonists had established track records and were specifically chosen to increase antibody titers, broaden responses, and improve durability in COVID‑19 protein vaccine candidates [5] [6] [7].
2. Which adjuvants were actually used in 2020–2021 COVID‑19 vaccines
The major, documented adjuvants in advanced COVID‑19 candidates were Matrix‑M (Novavax’s NVX‑CoV2373), saponin‑based and derived from Quillaja saponaria, and emulsion systems like MF59/AS03 which were evaluated or committed for COVID programs; CpG‑1018 (a TLR9 agonist) and aluminum salts were also used or tested in multiple candidates worldwide [4] [6] [8]. Scientific reviews name AS03, MF59 and CpG‑1018 as adjuvants already licensed for other vaccines and repurposed or supplied for COVID work [6].
3. What mRNA and vector vaccines used instead of “traditional” adjuvants
Pfizer‑BioNTech and Moderna’s mRNA vaccines did not include aluminum salts or classical adjuvants; their immunogenicity derives from the mRNA payload plus the lipid nanoparticle (LNP) delivery system, which both protects RNA and promotes immune recognition. Regulatory ingredient lists and educational summaries emphasize that those mRNA vaccines have lipids (including PEG‑linked lipids), sugars (sucrose) and buffers but no preservative or alum adjuvant in their authorized formulations [1] [2] [9].
4. Preservatives and multi‑dose safety: what was and wasn’t present
Many regulatory fact sheets and early labels make clear that the first mRNA products authorized in late 2020 did not contain preservatives intended to allow multi‑dose vial reuse; Pfizer’s vaccine, for example, was noted as not containing preservatives in early product information [9]. Public‑facing vaccine ingredient guides likewise stress that not all vaccines need preservatives and that preservative use depends on vial presentation and supply logistics [1].
5. Why particular adjuvants were chosen — supply, speed and immunology
Manufacturers and public‑health partners leaned on adjuvants already licensed or stockpiled (MF59, AS03, CpG‑1018, Matrix‑M) to accelerate development because those adjuvants came with safety and manufacturing knowledge, enabling faster trials and scaling. Scientific commentary early in the pandemic warned that there were relatively few widely available adjuvants and that having them ready could be decisive for pandemic responses [10] [6].
6. Disagreement, gaps and common misconceptions
Sources converge that mRNA vaccines lacked traditional adjuvants and that protein vaccines used adjuvants like Matrix‑M; they also document aluminum’s long history in vaccines generally [1] [11]. Claims circulating online about exotic additives (graphene oxide, microchips, luciferase) are not supported in the cited regulatory or scientific literature; authoritative ingredient lists and fact sheets list lipids, buffers, salts, sucrose and, for some protein vaccines, specified adjuvants [2] [9]. Available sources do not mention the presence of industrial contaminants alleged in some fringe reports [12].
7. Takeaway for readers weighing benefits and risks
The choice of adjuvant or lipid formulation was driven by vaccine platform, immunological need and the pragmatic goal of rapid, scalable manufacture. Reviews and regulatory summaries from 2020–2021 show that adjuvants were repurposed from licensed platforms to improve immune responses where needed, and that mRNA vaccines relied on LNP chemistry rather than classical adjuvants or preservatives [5] [4] [9]. Limitations: this synthesis uses the provided sources and therefore does not catalog every global candidate; for vaccine‑specific, up‑to‑date ingredient lists consult official EUA/labeling documents and manufacturers [1] [9].